The results come two weeks after Pfizer slashed its full-year adjusted earnings and revenue guidance and launched a sweeping $3.5 billion cost-cutting plan.
on Tuesday reported a narrower than expected loss for the third quarter as the drugmaker recorded charges largely related to struggles for$5.6 billion charge
The pharmaceutical giant also reiterated the full-year adjusted earnings and revenue guidance it announced two weeks ago, which is drastically lower than its initial projections due to weakening demand for its Covid products. That decline in demand also led Pfizer to announce a sweeping $3.5 billion cost-cutting plan at the same time.
Pfizer reiterated the guidance it outlined in October: The company expects 2023 sales of $58 billion to $61 billion and full-year adjusted earnings of $1.45 to $1.65 per share.Australia says it won't bid for the 2034 World Cup, clearing the way for Saudi Arabia to host
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
COVID Meds Like Paxlovid Will Soon Have Big Price TagsAmericans have been getting COVID treatments such as Paxlovid for free, but that's about to end. The medications will enter the private market this week, the Associated Press reported.
Weiterlesen »
COVID Meds Like Paxlovid Will Soon Have Big Price TagsAmericans have been getting COVID treatments such as Paxlovid for free, but that's about to end.
Weiterlesen »
Pfizer swings to quarterly loss due to COVID products write-offPfizer (PFE.N) on Tuesday reported its first quarterly loss since 2019, as the U.S. drugmaker recorded $5.6 billion in charges related to its COVID products such as its antiviral treatment Paxlovid and vaccine Comirnaty.
Weiterlesen »
Pfizer RSV vaccine lags GSK’s as head-to-head competition underwayPfizer RSV vaccine lags GSK’s as head-to-head competition underway
Weiterlesen »
Pfizer RSV vaccine lags GSK’s as head-to-head competition underwayPfizer (PFE.N), which dominated COVID vaccine sales, now finds itself looking up at GSK (GSK.L), whose rival new respiratory syncytial virus (RSV) vaccine has surged to an early lead since the shots launched this summer.
Weiterlesen »
Drug Stocks Keep Falling on Earnings. It Could Be a Long Week.Companies scheduled to report their results include Pfizer, GSK, Eli Lilly, and Novo Nordisk.
Weiterlesen »